Multiple Myeloma Management 與 SurvivorNet 使用情況與統計

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.
  • Apple App Store
  • 免費版
  • 醫療

商店排名

- -

We believe far too many people still struggle to find information about treatments that can save their lives. SurvivorNet is closing this gap by creating a deep, video-based educational resource for patients featuring top physicians and researchers around the country. To create patient-focused educational content, the company is working with physicians at leading NCCN-designated cancer centers such as The National Cancer Institute, Dana-Farber, Memorial Sloan Kettering, Stanford, NYU, and M.D. Anderson.
  • Apple App Store
  • 免費版
  • 健康與健身

商店排名

- -

Multiple Myeloma Management與 SurvivorNet 比較排名

比較過去 28 天的 Multiple Myeloma Management 排名趨勢與 SurvivorNet

排名

無可用數據

各國 Multiple Myeloma Management vs. SurvivorNet 排名比較

比較過去 28 天的 Multiple Myeloma Management 排名趨勢與 SurvivorNet

無可顯示數據

使用我們的免費試用版,與所有網站進行比較

立即開始
Multiple Myeloma Management VS.
SurvivorNet

12月 19, 2024